Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 to enhance platelet engraftment after allogeneic HSCT
ChiCTR2500096407Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of romiplostim in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and hematopoietic malignancies (2 cohorts), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Time to platelet engraftment. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2500096407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096407.